A new preclinical study by Mass Eye and Ear investigators showed that a novel mRNA-based therapy may be able to prevent blindness and scarring from proliferative vitreoretinopathy (PVR) following a ...

COVID-19, influenza, and respiratory syncytial virus vaccination coverage is low among adults so far this respiratory virus season (2024 to 2025).

Seasonal maternal respiratory syncytial virus vaccination and nirsevimab for infants demonstrate cost-effectiveness.

We recently compiled a list of the 10 Worst Performing Healthcare Stocks in 2024. In this article, we are going to take a ...